EuropaBio lobbies for better Orphan Drug rules
EuropaBio has responded to the European Commissions public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.
Cardior bags 64m in Series B Financing
Cardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure.
ERS Genomics and Cellular Engineering Technologies collaborating
ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.
Visus Therapeutics cashes in 20m from LSP
Visus Therapeutics has baged a 20m stock financing to advance development of Brimochol for presbyopia
British drug developer Mission Therapeutics plc earns $20m milestone
British drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.
Spectricity raises 14m in Series B round
Belgian semiconductor specialist Spectricity BV has baged 14m to speed up the development of mobile hyperspectral sensors for medical applications.
Abcam to acquire BioVision for $340m
Life sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.
Byondis and Glycotope merge platforms to target carbohydrates
Cancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement.
Artios Pharma Ltd raises US-$153m Series C financing
Cancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline.